These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 4456974

  • 21. Letter: Fattening of parkinsonians: a hypothalamic side effect of L-dopa?
    Gasparini M, Spinnler H.
    Med J Aust; 1975 Oct 11; 2(15):617. PubMed ID: 1196229
    [No Abstract] [Full Text] [Related]

  • 22. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
    Melamed E, Bitton V, Zelig O.
    Clin Neuropharmacol; 1986 Oct 11; 9(2):182-8. PubMed ID: 3085928
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.
    Skalabrin EJ, Laws ER, Bennett JP.
    Mov Disord; 1998 Sep 11; 13(5):775-81. PubMed ID: 9756145
    [Abstract] [Full Text] [Related]

  • 26. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM, Kostrzewa JP, Brus R.
    Amino Acids; 2002 Sep 11; 23(1-3):57-63. PubMed ID: 12373519
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ, Evtushenko SK, Dukhovnaia MA.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984 Sep 11; 84(9):1334-8. PubMed ID: 6506979
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ, Hume PM, Morris JG, Dean RT.
    J Neurochem; 2006 Aug 11; 98(4):1061-7. PubMed ID: 16771833
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W.
    Nervenarzt; 1995 Dec 11; 66(12):933-41. PubMed ID: 8584079
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.
    Granerus AK, Jagenburg R, Svanborg A.
    Naunyn Schmiedebergs Arch Pharmacol; 1973 Dec 11; 280(4):429-39. PubMed ID: 4274706
    [No Abstract] [Full Text] [Related]

  • 38. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility.
    Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, Shoulson I.
    Neurology; 1988 Mar 11; 38(3):419-21. PubMed ID: 3126408
    [Abstract] [Full Text] [Related]

  • 39. [Absorption, excretion, and clinical effects of L-dopa preparation with superenteric coating in parkinsonism (author's transl)].
    Tohgi H, Ogawa M.
    No To Shinkei; 1977 Aug 11; 29(8):873-8. PubMed ID: 907761
    [No Abstract] [Full Text] [Related]

  • 40. Slowly absorbed L-dopa preparation in the treatment of parkinsonism.
    Laitinen LV.
    Acta Neurol Scand; 1973 Aug 11; 49(3):331-8. PubMed ID: 4747020
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.